| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Erythrocytes | 20 | 2005 | 232 | 1.520 |
Why?
|
| Glycolates | 6 | 2005 | 11 | 1.050 |
Why?
|
| Ethylene Glycols | 6 | 2005 | 8 | 0.920 |
Why?
|
| Hemolysis | 9 | 2005 | 114 | 0.820 |
Why?
|
| Anemia, Sickle Cell | 14 | 2011 | 346 | 0.710 |
Why?
|
| Hematology | 2 | 2012 | 43 | 0.580 |
Why?
|
| Erythrocytes, Abnormal | 7 | 2011 | 20 | 0.430 |
Why?
|
| Solvents | 2 | 2005 | 46 | 0.400 |
Why?
|
| Erythrocyte Inclusions | 1 | 2012 | 2 | 0.380 |
Why?
|
| Clinical Clerkship | 4 | 2009 | 87 | 0.330 |
Why?
|
| Endothelium, Vascular | 5 | 2011 | 499 | 0.300 |
Why?
|
| Erythropoiesis | 5 | 1997 | 43 | 0.280 |
Why?
|
| Space Flight | 5 | 1997 | 170 | 0.260 |
Why?
|
| Hodgkin Disease | 2 | 2025 | 304 | 0.230 |
Why?
|
| Hemolysin Proteins | 1 | 2005 | 30 | 0.230 |
Why?
|
| Safety-net Providers | 1 | 2025 | 71 | 0.220 |
Why?
|
| Erythrocyte Deformability | 2 | 1994 | 3 | 0.220 |
Why?
|
| Carcinogens | 1 | 2004 | 135 | 0.210 |
Why?
|
| Cytoplasmic Granules | 1 | 2004 | 51 | 0.210 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 2005 | 37 | 0.200 |
Why?
|
| Endothelin-1 | 1 | 2002 | 45 | 0.190 |
Why?
|
| Epoprostenol | 1 | 2002 | 46 | 0.190 |
Why?
|
| Physical Examination | 1 | 2001 | 165 | 0.170 |
Why?
|
| Rats | 6 | 2005 | 3682 | 0.170 |
Why?
|
| Internal Medicine | 3 | 2009 | 159 | 0.150 |
Why?
|
| Hemoglobins, Abnormal | 1 | 1999 | 13 | 0.150 |
Why?
|
| Blood Volume | 3 | 1996 | 82 | 0.150 |
Why?
|
| Endothelium | 3 | 1987 | 70 | 0.150 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 343 | 0.150 |
Why?
|
| Hydroxyurea | 1 | 1999 | 87 | 0.140 |
Why?
|
| Calcium | 5 | 2005 | 1084 | 0.140 |
Why?
|
| Anemia, Aplastic | 2 | 1997 | 62 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2005 | 1704 | 0.140 |
Why?
|
| Fasciitis | 1 | 1997 | 20 | 0.130 |
Why?
|
| History, 20th Century | 2 | 2012 | 396 | 0.130 |
Why?
|
| Rats, Inbred F344 | 3 | 2005 | 98 | 0.130 |
Why?
|
| Cell Adhesion | 7 | 2011 | 340 | 0.130 |
Why?
|
| Adult | 24 | 2025 | 31723 | 0.120 |
Why?
|
| Humans | 50 | 2025 | 133015 | 0.120 |
Why?
|
| Osmotic Fragility | 3 | 2003 | 5 | 0.120 |
Why?
|
| Eosinophilia | 1 | 1997 | 106 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2004 | 3676 | 0.110 |
Why?
|
| Physician Executives | 3 | 2009 | 39 | 0.110 |
Why?
|
| Spherocytosis, Hereditary | 1 | 1994 | 8 | 0.110 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 818 | 0.110 |
Why?
|
| Erythrocyte Aging | 4 | 1997 | 8 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 4717 | 0.100 |
Why?
|
| Acetylcysteine | 1 | 2013 | 84 | 0.100 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2013 | 57 | 0.100 |
Why?
|
| Animals | 9 | 2012 | 35898 | 0.100 |
Why?
|
| Hemoglobin SC Disease | 2 | 1999 | 11 | 0.100 |
Why?
|
| Male | 25 | 2025 | 65312 | 0.090 |
Why?
|
| France | 1 | 2012 | 89 | 0.090 |
Why?
|
| Bone Marrow | 4 | 1997 | 333 | 0.090 |
Why?
|
| History, 19th Century | 1 | 2012 | 120 | 0.090 |
Why?
|
| Erythrocyte Membrane | 2 | 2011 | 24 | 0.090 |
Why?
|
| Sulfoglycosphingolipids | 1 | 2011 | 8 | 0.090 |
Why?
|
| Sickle Cell Trait | 2 | 1987 | 11 | 0.090 |
Why?
|
| Hematocrit | 3 | 2001 | 117 | 0.080 |
Why?
|
| Species Specificity | 2 | 2005 | 561 | 0.080 |
Why?
|
| Erythrocyte Indices | 5 | 2003 | 17 | 0.080 |
Why?
|
| Specialty Boards | 1 | 2009 | 20 | 0.080 |
Why?
|
| Achievement | 1 | 2009 | 32 | 0.080 |
Why?
|
| Licensure, Medical | 1 | 2009 | 22 | 0.080 |
Why?
|
| Interleukin-1 | 2 | 2002 | 136 | 0.080 |
Why?
|
| Middle Aged | 14 | 2025 | 29016 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 3 | 2000 | 618 | 0.070 |
Why?
|
| Lutheran Blood-Group System | 1 | 1987 | 1 | 0.070 |
Why?
|
| Female | 20 | 2025 | 71346 | 0.070 |
Why?
|
| Cations | 2 | 2002 | 39 | 0.070 |
Why?
|
| Cells, Cultured | 5 | 2002 | 3120 | 0.060 |
Why?
|
| In Vitro Techniques | 3 | 2002 | 913 | 0.060 |
Why?
|
| Histiocytes | 1 | 1986 | 25 | 0.060 |
Why?
|
| Typhoid Fever | 1 | 1986 | 19 | 0.060 |
Why?
|
| Erythropoietin | 3 | 1996 | 110 | 0.060 |
Why?
|
| Pancytopenia | 1 | 1986 | 41 | 0.060 |
Why?
|
| Splenic Infarction | 1 | 1985 | 4 | 0.060 |
Why?
|
| Phagocytosis | 1 | 1986 | 194 | 0.060 |
Why?
|
| Osmolar Concentration | 1 | 2005 | 177 | 0.060 |
Why?
|
| Plasma Cells | 1 | 2005 | 57 | 0.060 |
Why?
|
| Potassium Channel Blockers | 1 | 2005 | 85 | 0.060 |
Why?
|
| Microscopy, Phase-Contrast | 2 | 2002 | 18 | 0.060 |
Why?
|
| Cocarcinogenesis | 1 | 2004 | 16 | 0.060 |
Why?
|
| Carcinogenicity Tests | 1 | 2004 | 21 | 0.060 |
Why?
|
| Kupffer Cells | 1 | 2004 | 21 | 0.060 |
Why?
|
| Inhalation Exposure | 1 | 2004 | 36 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2005 | 344 | 0.050 |
Why?
|
| Hemangiosarcoma | 1 | 2004 | 46 | 0.050 |
Why?
|
| Spherocytes | 1 | 2003 | 2 | 0.050 |
Why?
|
| Hemoglobin C Disease | 1 | 2003 | 3 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2004 | 318 | 0.050 |
Why?
|
| Anemia, Sideroblastic | 1 | 2004 | 17 | 0.050 |
Why?
|
| Hypotonic Solutions | 1 | 2003 | 14 | 0.050 |
Why?
|
| Spleen | 1 | 1985 | 287 | 0.050 |
Why?
|
| Curriculum | 1 | 2009 | 764 | 0.050 |
Why?
|
| Dermatan Sulfate | 1 | 2003 | 4 | 0.050 |
Why?
|
| beta-Thalassemia | 1 | 2003 | 30 | 0.050 |
Why?
|
| Chondroitin Sulfates | 1 | 2003 | 15 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 2004 | 223 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 2 | 2005 | 675 | 0.050 |
Why?
|
| Heparitin Sulfate | 1 | 2003 | 21 | 0.050 |
Why?
|
| Densitometry | 1 | 2002 | 20 | 0.050 |
Why?
|
| Filtration | 1 | 2002 | 23 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2005 | 204 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2000 | 77 | 0.050 |
Why?
|
| Time Factors | 4 | 2004 | 6483 | 0.050 |
Why?
|
| Career Mobility | 1 | 2003 | 54 | 0.050 |
Why?
|
| Kinetics | 2 | 2002 | 1312 | 0.050 |
Why?
|
| Cell Size | 1 | 2002 | 87 | 0.050 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2002 | 9 | 0.050 |
Why?
|
| Hemorheology | 1 | 2002 | 26 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2004 | 712 | 0.050 |
Why?
|
| Carboxyhemoglobin | 1 | 2001 | 10 | 0.050 |
Why?
|
| Aged | 6 | 2025 | 21483 | 0.050 |
Why?
|
| Lymphoma | 1 | 2005 | 333 | 0.050 |
Why?
|
| Heparin | 1 | 2003 | 228 | 0.050 |
Why?
|
| United States | 4 | 2012 | 11649 | 0.050 |
Why?
|
| Plasma Volume | 3 | 1996 | 15 | 0.050 |
Why?
|
| Hospitals, County | 1 | 2021 | 24 | 0.040 |
Why?
|
| Flow Cytometry | 3 | 1996 | 814 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2003 | 235 | 0.040 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2001 | 12 | 0.040 |
Why?
|
| Remission Induction | 1 | 2002 | 309 | 0.040 |
Why?
|
| DNA Damage | 1 | 2004 | 517 | 0.040 |
Why?
|
| Weightlessness | 3 | 1997 | 80 | 0.040 |
Why?
|
| Prekallikrein | 1 | 1980 | 1 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 1989 | 905 | 0.040 |
Why?
|
| Kallikreins | 1 | 1980 | 31 | 0.040 |
Why?
|
| Leukemia, Lymphoid | 1 | 1980 | 108 | 0.040 |
Why?
|
| Indicators and Reagents | 1 | 2000 | 52 | 0.040 |
Why?
|
| Adolescent | 4 | 2025 | 20557 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2000 | 41 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2000 | 77 | 0.040 |
Why?
|
| Calmodulin | 1 | 2001 | 212 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2002 | 149 | 0.040 |
Why?
|
| HIV Infections | 2 | 2003 | 2025 | 0.040 |
Why?
|
| Potassium Channels | 1 | 2001 | 161 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2000 | 130 | 0.040 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2002 | 153 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 1980 | 110 | 0.040 |
Why?
|
| Peptide Fragments | 2 | 2001 | 811 | 0.040 |
Why?
|
| Platelet Count | 2 | 2013 | 141 | 0.040 |
Why?
|
| Erythroid Precursor Cells | 2 | 1997 | 24 | 0.040 |
Why?
|
| Young Adult | 2 | 2025 | 9966 | 0.040 |
Why?
|
| von Willebrand Factor | 2 | 1993 | 205 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2001 | 329 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2001 | 376 | 0.040 |
Why?
|
| Blood Platelets | 2 | 1995 | 334 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 2004 | 565 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2003 | 624 | 0.040 |
Why?
|
| Conjugation, Genetic | 1 | 1978 | 8 | 0.040 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 1997 | 3 | 0.030 |
Why?
|
| Education, Medical | 1 | 2001 | 306 | 0.030 |
Why?
|
| Erythrocyte Volume | 1 | 1997 | 4 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2025 | 12963 | 0.030 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 1997 | 29 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 1978 | 143 | 0.030 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1997 | 27 | 0.030 |
Why?
|
| Bone Marrow Cells | 2 | 1996 | 269 | 0.030 |
Why?
|
| Adrenal Insufficiency | 1 | 1997 | 33 | 0.030 |
Why?
|
| Isoantibodies | 1 | 1996 | 59 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2000 | 506 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 7165 | 0.030 |
Why?
|
| Iron | 2 | 1996 | 303 | 0.030 |
Why?
|
| Pain | 1 | 1999 | 461 | 0.030 |
Why?
|
| Reticulocyte Count | 1 | 1995 | 2 | 0.030 |
Why?
|
| Cell Cycle | 1 | 1978 | 619 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 1995 | 69 | 0.030 |
Why?
|
| Erythrocyte Transfusion | 1 | 1996 | 136 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2025 | 17415 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1978 | 440 | 0.030 |
Why?
|
| Hemoglobin, Sickle | 1 | 1995 | 20 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 1995 | 176 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2000 | 571 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2004 | 1401 | 0.030 |
Why?
|
| ADAMTS13 Protein | 1 | 2013 | 67 | 0.030 |
Why?
|
| Hepatitis C | 1 | 1997 | 388 | 0.030 |
Why?
|
| ADAM Proteins | 1 | 2013 | 87 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 1408 | 0.030 |
Why?
|
| Rheology | 2 | 1996 | 35 | 0.020 |
Why?
|
| Intracellular Fluid | 1 | 1992 | 25 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 1244 | 0.020 |
Why?
|
| Mice | 2 | 2011 | 18897 | 0.020 |
Why?
|
| Oxygen | 1 | 1995 | 572 | 0.020 |
Why?
|
| Canada | 2 | 2003 | 336 | 0.020 |
Why?
|
| Sulfotransferases | 1 | 2011 | 27 | 0.020 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 2011 | 28 | 0.020 |
Why?
|
| Protein Engineering | 1 | 2011 | 66 | 0.020 |
Why?
|
| Single-Chain Antibodies | 1 | 2011 | 45 | 0.020 |
Why?
|
| Water | 1 | 1992 | 198 | 0.020 |
Why?
|
| Adaptation, Physiological | 3 | 1997 | 283 | 0.020 |
Why?
|
| Mutation | 1 | 2004 | 6314 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 1744 | 0.020 |
Why?
|
| Apoptosis | 1 | 1997 | 1922 | 0.020 |
Why?
|
| Preceptorship | 1 | 2009 | 31 | 0.020 |
Why?
|
| Problem-Based Learning | 1 | 2009 | 73 | 0.020 |
Why?
|
| Oligopeptides | 2 | 2001 | 120 | 0.020 |
Why?
|
| Hemorrhage | 1 | 1992 | 516 | 0.020 |
Why?
|
| Career Choice | 1 | 2009 | 163 | 0.020 |
Why?
|
| Blood Circulation | 1 | 1987 | 20 | 0.020 |
Why?
|
| Videotape Recording | 1 | 1987 | 58 | 0.020 |
Why?
|
| Receptors, Mitogen | 1 | 1987 | 4 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1987 | 132 | 0.020 |
Why?
|
| Aging | 1 | 1994 | 1273 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1987 | 118 | 0.020 |
Why?
|
| Cell Communication | 1 | 1987 | 189 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2003 | 3862 | 0.020 |
Why?
|
| Faculty, Medical | 1 | 2009 | 279 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 1987 | 261 | 0.020 |
Why?
|
| Hyperplasia | 1 | 1986 | 200 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 2 | 1995 | 1053 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 1987 | 443 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 2832 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2005 | 18 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2009 | 448 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2005 | 119 | 0.010 |
Why?
|
| Herpesvirus 8, Human | 1 | 2005 | 50 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1985 | 147 | 0.010 |
Why?
|
| Splenomegaly | 1 | 1985 | 33 | 0.010 |
Why?
|
| Umbilical Veins | 2 | 1996 | 73 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 178 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 477 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2001 | 2763 | 0.010 |
Why?
|
| Atrophy | 1 | 1985 | 253 | 0.010 |
Why?
|
| Hemoglobin C | 1 | 2003 | 2 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2001 | 3936 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2005 | 499 | 0.010 |
Why?
|
| Homosexuality | 1 | 2003 | 15 | 0.010 |
Why?
|
| Reed-Sternberg Cells | 1 | 2003 | 7 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 440 | 0.010 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2003 | 67 | 0.010 |
Why?
|
| Vinblastine | 1 | 2003 | 58 | 0.010 |
Why?
|
| Antithrombins | 1 | 2003 | 61 | 0.010 |
Why?
|
| Pedigree | 1 | 1987 | 1731 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2003 | 195 | 0.010 |
Why?
|
| Bleomycin | 1 | 2003 | 114 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2003 | 106 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2011 | 3981 | 0.010 |
Why?
|
| Dacarbazine | 1 | 2003 | 99 | 0.010 |
Why?
|
| Authorship | 1 | 2003 | 31 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 2003 | 63 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2003 | 278 | 0.010 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2005 | 293 | 0.010 |
Why?
|
| Fibronectins | 2 | 1996 | 110 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 361 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2003 | 2185 | 0.010 |
Why?
|
| Reticulocytes | 1 | 2001 | 44 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2003 | 378 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2009 | 1068 | 0.010 |
Why?
|
| Awards and Prizes | 1 | 2003 | 70 | 0.010 |
Why?
|
| Graft vs Host Reaction | 1 | 1981 | 11 | 0.010 |
Why?
|
| Homozygote | 1 | 2003 | 560 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2003 | 302 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 1583 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 621 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2003 | 270 | 0.010 |
Why?
|
| Heterozygote | 1 | 2003 | 729 | 0.010 |
Why?
|
| Ribonucleases | 1 | 2001 | 51 | 0.010 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2001 | 12 | 0.010 |
Why?
|
| Physician's Role | 1 | 2003 | 171 | 0.010 |
Why?
|
| Bilirubin | 1 | 2001 | 131 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2001 | 144 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2005 | 788 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 2001 | 154 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 2000 | 37 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2001 | 432 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2000 | 44 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2000 | 82 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 5160 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2001 | 909 | 0.010 |
Why?
|
| Karyotyping | 1 | 2000 | 320 | 0.010 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2000 | 126 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2001 | 1013 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 1098 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 1448 | 0.010 |
Why?
|
| Biopsy | 1 | 2003 | 1298 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2003 | 1374 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2001 | 541 | 0.010 |
Why?
|
| Thrombosis | 1 | 2003 | 540 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 1316 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2000 | 776 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 2000 | 362 | 0.010 |
Why?
|
| Thrombophlebitis | 1 | 1997 | 20 | 0.010 |
Why?
|
| Abortion, Habitual | 1 | 1997 | 18 | 0.010 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 1996 | 17 | 0.010 |
Why?
|
| Chromium Radioisotopes | 1 | 1996 | 3 | 0.010 |
Why?
|
| Protein Binding | 1 | 2001 | 1833 | 0.010 |
Why?
|
| Radioisotope Dilution Technique | 1 | 1996 | 43 | 0.010 |
Why?
|
| Receptors, Vitronectin | 1 | 1996 | 3 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 2143 | 0.010 |
Why?
|
| E-Selectin | 1 | 1996 | 43 | 0.010 |
Why?
|
| Smoking | 1 | 2001 | 945 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1996 | 213 | 0.010 |
Why?
|
| Hippocampus | 1 | 2001 | 825 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 1348 | 0.010 |
Why?
|
| Perfusion | 1 | 1996 | 204 | 0.010 |
Why?
|
| Bucladesine | 1 | 1995 | 20 | 0.010 |
Why?
|
| Iloprost | 1 | 1995 | 8 | 0.010 |
Why?
|
| Diffusion | 1 | 1995 | 58 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2005 | 2718 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 1996 | 292 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1997 | 342 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1995 | 75 | 0.010 |
Why?
|
| Blood Gas Analysis | 1 | 1995 | 86 | 0.010 |
Why?
|
| Platelet Activation | 1 | 1995 | 71 | 0.010 |
Why?
|
| Blood | 1 | 1995 | 105 | 0.010 |
Why?
|
| Platelet Aggregation | 1 | 1995 | 115 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2001 | 2865 | 0.010 |
Why?
|
| Temperature | 1 | 1995 | 321 | 0.010 |
Why?
|
| Genotype | 1 | 2000 | 2719 | 0.010 |
Why?
|
| Recurrence | 1 | 1997 | 1465 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1996 | 616 | 0.010 |
Why?
|
| Aspirin | 1 | 1995 | 231 | 0.010 |
Why?
|
| Homeostasis | 1 | 1997 | 745 | 0.010 |
Why?
|
| Polymers | 1 | 1993 | 117 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2000 | 2632 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2001 | 3990 | 0.010 |
Why?
|
| Chemistry | 1 | 1987 | 59 | 0.000 |
Why?
|
| Chemical Phenomena | 1 | 1987 | 87 | 0.000 |
Why?
|
| Pregnancy | 1 | 1997 | 7588 | 0.000 |
Why?
|
| Viscosity | 1 | 1982 | 42 | 0.000 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1981 | 7 | 0.000 |
Why?
|
| Hydrochloric Acid | 1 | 1981 | 13 | 0.000 |
Why?
|
| Sodium Hydroxide | 1 | 1981 | 8 | 0.000 |
Why?
|
| Potassium | 1 | 1982 | 275 | 0.000 |
Why?
|
| Histocompatibility Testing | 1 | 1981 | 111 | 0.000 |
Why?
|
| Phosphates | 1 | 1981 | 117 | 0.000 |
Why?
|
| Sodium | 1 | 1982 | 293 | 0.000 |
Why?
|
| HLA Antigens | 1 | 1981 | 220 | 0.000 |
Why?
|
| Leukemia | 1 | 1981 | 374 | 0.000 |
Why?
|